|Articles|January 1, 2015

Survey sound off

We’re still hearing from you about our second annual Issues & Attitudes Survey, such as these comments from your pediatric colleague in Succasunna, NJ.

Click here to see the complete results of our 2014 second annual Issues & Attitudes Survey.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe

Related Content

FDA expands TOFIDENCE (tocilizumab-bavi) indications to include CAR T-cell–induced CRS and pediatric COVID-19

ByMorgan Ebert, Executive Editor

June 10th 2026

FDA accepts vedolizumab sBLA for pediatric ulcerative colitis and Crohn's disease

ByMorgan Ebert, Executive Editor

June 10th 2026

FDA approves lebrikizumab every-8-week maintenance dosing for moderate-to-severe atopic dermatitis

ByMorgan Ebert, Executive Editor

June 10th 2026

New sunscreen ingredient clears FDA for the first time since the 1990s

ByMorgan Ebert, Executive Editor

June 9th 2026

FDA grants GEn-1123 rare disease designations for Duchenne muscular dystrophy

ByMorgan Ebert, Executive Editor

June 9th 2026

Latest CME

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Survey sound off

Related Content

FDA expands TOFIDENCE (tocilizumab-bavi) indications to include CAR T-cell–induced CRS and pediatric COVID-19

FDA accepts vedolizumab sBLA for pediatric ulcerative colitis and Crohn's disease

FDA approves lebrikizumab every-8-week maintenance dosing for moderate-to-severe atopic dermatitis

New sunscreen ingredient clears FDA for the first time since the 1990s

FDA grants GEn-1123 rare disease designations for Duchenne muscular dystrophy

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Contemporary Pediatrics

FDA grants GEn-1123 rare disease designations for Duchenne muscular dystrophy

FDA accepts vedolizumab sBLA for pediatric ulcerative colitis and Crohn's disease

New sunscreen ingredient clears FDA for the first time since the 1990s

FDA approves lebrikizumab every-8-week maintenance dosing for moderate-to-severe atopic dermatitis

Earlier egg introduction guidelines linked to measurable decline in infant egg allergy prevalence